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Abstract
Purpose The folate receptor (FR) is frequently overexpressed in a variety of tumor types and, hence, an interesting target for
radionuclide therapy. The aim of this study was to evaluate a new class of albumin-binding radioconjugates comprising 5-
methyltetrahydrofolate (5-MTHF) as a targeting agent and to compare their properties with those of the previously established
folic acid-based [177Lu]Lu-OxFol-1.
Methods [177Lu]Lu-6R-RedFol-1 and [177Lu]Lu-6S-RedFol-1 were investigated in vitro using FR-positive KB tumor cells.
Biodistribution studies were performed in KB tumor-bearing mice, and the areas under the curve (AUC0→ 120h) were determined
for the uptake in tumors and kidneys. [177Lu]Lu-6R-RedFol-1 was compared with [177Lu]Lu-OxFol-1 in a therapy study over
8 weeks using KB tumor-bearing mice.
Results Both radioconjugates demonstrated similar in vitro properties as [177Lu]Lu-OxFol-1; however, the tumor uptake of
[177Lu]Lu-6R-RedFol-1 and [177Lu]Lu-6S-RedFol-1 was significantly increased in comparison with [177Lu]Lu-OxFol-1. In
the case of [177Lu]Lu-6S-RedFol-1, also the kidney uptake was increased; however, renal retention of [177Lu]Lu-6R-RedFol-1
was similar to that of [177Lu]Lu-OxFol-1. This led to an almost 4-fold increased tumor-to-kidney AUC0→ 120h ratio of [
177Lu]Lu-
6R-RedFol-1 as compared with [177Lu]Lu-6S-RedFol-1 and [177Lu]Lu-OxFol-1. At equal activity, the therapeutic effect of
[177Lu]Lu-6R-RedFol-1 was better than that of [177Lu]Lu-OxFol-1, reflected by a slower tumor growth and, consequently, an
increased median survival time (49 days vs. 34 days).
Conclusion This study demonstrated the promising potential of 5-MTHF-based radioconjugates for FR-targeting. Application of
[177Lu]Lu-6R-RedFol-1 resulted in unprecedentedly high tumor-to-kidney ratios and, as a consequence, a superior therapeutic
effect as compared with [177Lu]Lu-OxFol-1. These findings, together with the absence of early side effects, make [177Lu]Lu-6R-
RedFol-1 attractive in view of a future clinical translation.
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Introduction
Targeted radionuclide therapy emerged as a promising con-
cept for the palliative treatment of metastasized cancer using
β−-particle-emitting radionuclides in combination with a spe-
cific tumor-targeting agent [1, 2]. The experience made with
somatostatin receptor-targeted radiopeptides (e.g., [177Lu]Lu-
DOTATATE [3, 4]) and prostate-specific membrane antigen
(PSMA)-targeted radioligands (e.g., [177Lu]Lu-PSMA-617
[5, 6]) is encouraging to further explore suitable targets and
develop radiopharmaceuticals to enable the treatment of addi-
tional tumor types.
The folate receptor (FR) is a membrane-anchored glyco-
protein, which is overexpressed in gynecological and other
tumor types, including lung, breast, and colon cancers [7–9].
Folic acid radioconjugates have been translated to clinics for
nuclear imaging of FR-positive tumors [10, 11]; however,
their therapeutic exploitation remains challenging. The rela-
tively low tumor-to-kidney ratio of accumulated folate
radioconjugates would limit the applicable quantity of activity
in order to prevent the risk of damage to the kidneys [12].
The high renal uptake of folate-based radiopharmaceu-
ticals has been addressed with various strategies [13], in-
cluding pharmacological interactions [14–16]. A major
step forward was achieved by introducing an albumin-
binding entity into the structure of radiofolates to prolong
the i r b lood c i rcu la t ion [17 , 18] . The resu l t ing
radioconjugates revealed significantly increased tumor up-
take and improved tumor-to-kidney ratios, which enabled
their use in preclinical therapy studies in mice [17, 19]. The
therapeutic effects of this approach were promising; how-
ever, the kidneys remained the dose-limiting organ.
Recently, Boss et al. reported on results obtained with a
novel class of fluorine-18-based radiotracers, in which folic
acid (oxidized version of folate) was exchanged with the two
s t e r eo i somer s (6R and 6S , r e spec t ive ly ) o f 5 -
methyltetrahydrofolate (5-MTHF) [20, 21]. It was found that
6R-aza-[18F]fluoro-5-MTHF as well as 6S-aza-[18F]fluoro-5-
MTHF accumulated to a significantly higher extent in the
tumor tissue than aza-[18F]fluorofolic acid (18F-AzaFol), in
which folic acid was employed as a targeting agent [21].
Importantly, the 6R-aza-[18F]fluoro-5-MTHF isomer was
cleared much more effectively through the kidneys as com-
pared with 18F-AzaFol.
Thus, the aim of this study was to translate the concept of
using 5-MTHF as a targeting agent to albumin-binding DOTA
conjugates in order to increase the tumor uptake and possibly
reduce renal retention of activity. 6R-RedFol-1 and 6S-
RedFol-1, based on 6R-5-MTHF and 6S-5-MTHF, respective-
ly, were designed as structural equivalents to the previously
developed albumin-binding DOTA-folate conjugate (cm10,
herein referred to as OxFol-1 [18]) (Fig. 1). 6R-RedFol-1
and 6S-RedFol-1 were labeled with lutetium-177 and
evaluated in vitro and in vivo for comparison of their charac-
teristics with those of [177Lu]Lu-OxFol-1 [18]. Therapy stud-
ies with KB tumor-bearing mice were performed in order to
compare the therapeutic effect of the more promising
[177Lu]Lu-RedFol-1 isomer with [177Lu]Lu-OxFol-1.
Materials and methods
Radiolabeling and in vitro stability of the folate
radioconjugates
The synthesis of 6R-RedFol-1 and 6S-RedFol-1 will be pub-
lished elsewhere. OxFol-1 (previously referred to as cm10)
was employed in previous preclinical studies [13, 22]. The
radiolabeling of the folate conjugates with lutetium-177
(T1/2= 6.65 days, Eβ−average = 134 keV, Eγ= 113 keV, 208 keV)
was performed at pH ~ 4.5 using no-carrier-added lutetium-
177 ([177Lu]LuCl3 in HCl 0.04 M; ITM Medical Isotopes
GmbH, Germany) to obtain molar activities of 10–50 MBq/
nmol (Supplementary Material). L-Ascorbic acid (6 mg) was
added to the labeling mixture of 6R-RedFol-1 and 6S-RedFol-
1 to prevent oxidation. Quality control was performed using
high-performance liquid chromatography (HPLC). Stability
of the radioconjugates (50 MBq/nmol) in phosphate-
buffered saline (PBS) pH 7.4 at an activity concentration of
100 MBq/500 μL was investigated over a period of 24 h
(Supplementary Material). Stability in human plasma
(Stiftung Blutspende SRK Aargau-Solothurn, Switzerland)
was also investigated over 24 h at 37 °C (Supplementary
Material).
Determination of logD values
Distribution coefficients (logD values) of the folate
radioconjugates were determined by a shake-flask method
using n-octanol and PBS pH 7.4 followed by phase separa-
tion, as previously reported (Supplementary Material) [18].
Binding affinity tomouse and human plasma proteins
To compare the plasma protein-binding properties of the fo-
late radioconjugates, the percentage of the fraction bound to
mouse and human plasma proteins was determined at variable
plasma dilutions calculated as [albumin]-to-[radioconjugate]
molar ratios. Determination of the binding affinity was per-
formed by measuring the free fraction of the radioconjugate
separated from the albumin-bound fraction using an ultrafil-
tration method as previously reported (Supplementary
Material) [23].
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Tumor cell culture and cell uptake studies
KB tumor cells (cervical carcinoma cell line, subclone
of HeLa cells, ACC-136) were purchased from the
German Collection of Microorganisms and Cell
Cultures (DSMZ, Germany). Cells were cultured in
folate-deficient RPMI medium (FFRPMI, Cell Culture
Technologies GmbH, Gravesano, Switzerland) supple-
mented with 10% fetal calf serum, L-glutamine, and
antibiotics.
Cellular uptake and internalization studies were performed
with all folate radioconjugates according to a previously pub-
lished procedure (Supplementary Material) [18]. The results
were expressed as percentage of total added activity and pre-
sented as average ± SD of 3–6 independent experiments per-
formed in triplicate.
In vivo studies
All applicable international, national, and/or institutional
guidelines for the care and use of animals were followed.
In particular, all animal experiments were carried out ac-
cording to the guidelines of Swiss Regulations for Animal
Welfare. The preclinical studies have been ethically ap-
proved by the Cantona l Commit tee of Animal
Experimentation and permitted by the responsible canton-
al authorities.
Five- to 6-week-old female, athymic nude mice (CD-1
Foxn-1/nu) were purchased from Char les River
Laboratories (Sulzfeld, Germany) and fed with a folate-
deficient rodent diet (ssniff Spezialdiäten GmbH; Soest,
Germany). Mice were subcutaneously inoculated with
KB tumor cells (5 × 106 cells in 100 μL PBS) on both
shoulders for biodistribution and imaging studies or with
KB tumor cells (4.5 × 106 cells in 100 μL PBS) on the right
shoulder for the therapy study.
In vivo stability of folate radioconjugates
In vivo stability studies were performed in mice without tu-
mors (n = 2), injected with the folate radioconjugates
(25 MBq, 0.5 nmol, 100 μL). After precipitation of proteins
in plasma of blood samples collected at 4 h p.i., the samples
were analyzed using HPLC (Supplementary Material).
Biodistribution studies
Biodistribution studies were performed 10–14 days after tu-
mor cell inoculation when the tumor size reached a volume of
~ 300 mm3. Mice (n = 4) were injected into a lateral tail vein
with the respective folate radioconjugate (3 MBq, 0.5 nmol,
100 μL) diluted in PBS containing 0.05% bovine serum albu-
min (BSA). The animals were sacrificed at various timepoints
up to 120 h after administration of the radioconjugates.
Additional mice (n = 3) were injected with excess folic acid
(100 μg in PBS pH 7.4), ~ 5 min prior to the folate
radioconjugates and sacrificed 1 h later (Supplementary
Material). Selected tissues and organs were collected,
weighed, and counted using a γ-counter (PerkinElmer,
Wallac Wizard 1480). The results were listed as a percentage
of the injected activity per gram (% IA/g) of tissue mass, using
counts of a defined volume of the original injection solution
measured at the same time, resulting in decay-corrected
values.
Determination of areas under the curve
Biodistribution data were converted to non-decay-corrected
values to obtain the time-dependent curves of accumulated
activity in the tumor xenografts, blood, kidneys, and liver.
The data points were used to calculate the areas under the
curve (AUC) using GraphPad Prism (version 7) as previously
reported [18]. The AUC0→ 120h values of the [
177Lu]Lu-
OxFol-1 were set as 1.0 to determine the relative values of
Fig. 1 Chemical structure of
OxFol-1 (green), 6R-RedFol-1
(blue), and 6S-RedFol-1 (red)




The acquisition and analysis of images were performed with a
dedicated small-animal SPECT/CT scanner (NanoSPECT/
CT™, Mediso Medical Imaging Systems, Budapest,
Hungary) as previously reported (Supplementary Material)
[18]. Mice were injected with the folate radioconjugates
(25MBq, 0.5 nmol) and scanned at 4 h and 24 h post injection
(p.i.) Images were prepared using VivoQuant post-processing
software (version 3.5, inviCRO Imaging Services and
Software, Boston, USA). A Gauss post-reconstruction filter
(FWHM= 1 mm) was applied, and the scale of activity was
set as indicated on the images.
Therapy study
Mice were randomly assigned to five groups consisting of 6–9
animals 4 days after tumor cell inoculation when tumors
reached an average size of 60–100 mm3. The mice were
injected with vehicle only (group A: PBS with 0.05% BSA;
control), 10 MBq [177Lu]Lu-6R-RedFol-1 (group B), or
10 MBq [177Lu]Lu-OxFol-1 (group C) at an amount of
0.5 nmol folate conjugate. Additional groups of mice were
injected with 15 MBq [177Lu]Lu-6R-RedFol-1 (group D) or
15 MBq [177Lu]Lu-OxFol-1 (group E) at an amount of
0.5 nmol folate conjugate (Table 1). The relative body weight
(RBW) was defined as [BWx/BW0], where BWx is the body
weight in gram at a given day x and BW0 is the body weight in
gram at day 0. The tumor dimensions were determined by
measuring the longest tumor axis (L) and its perpendicular
axis (W) with a digital caliper. The tumor volume (TV) was
calculated according to the equation [TV = 0.5 × (L ×W2)].
The relative tumor volume (RTV) was defined as [TVx/
TV0], where TVx is the tumor volume in cubic millimeters
at a given day x and TV0 is the tumor volume in cubic
millimeters at day 0. Endpoint criteria were defined as (i) a
tumor volume of ≥ 1000 mm3, (ii) loss of ≥ 15% of initial
body weight, (iii) a combination of a tumor size of ≥
800mm3 and bodyweight loss of ≥ 10% and/or (iv) ulceration
of the tumor, and/or (v) abnormal behavior, indicating pain or
unease. Mice were removed from the study and euthanized
when an endpoint was reached.
Assessment of the therapy study
The efficacy of the radionuclide therapy was assessed by de-
termination of the tumor growth delay (TGDx), which was
calculated as the time required for the tumor volume to in-
crease x-fold over the initial volume at day 0. The tumor
growth delay indices [TGDIx = TGDx(T)/TGDx(C)] were cal-
culated as the TGDx ratio of treated mice (T) over control mice
(C) for a 2-fold (x = 2, TGD2) and 5-fold (x = 5, TGD5) in-
crease of the initial tumor volume. The percentage of tumor
growth inhibition (TGI) was calculated as [100 − (RTVT/
RTVC × 100)], where RTVT is a relative tumor volume of
treated mice at day 14, when the first mouse of the control
group (group A) reached the endpoint and the average relative
tumor volume of control mice was RTVC.
The average of relative body weights of mice from each
group was compared with that of control mice at day 14 and at
the endpoint. Blood plasma parameters were determined once
an endpoint was reached or at the end of the study
(Supplementary Material). After euthanasia, the kidneys, liv-
er, spleen, and brain were collected and weighed. The organ
mass-to-brain ratios were calculated using the organ masses
collected at the day of euthanasia (Supplementary Material).
A full macroscopic examination was performed in each
animal, and the kidneys, bone marrow (sternum and femur),
and spleen were sampled for histological assessment as previ-
ously reported (Supplementary Material) [24]. Histological
lesions were semi-quantitatively scored by a veterinary pa-
thologist in a blind manner using a severity grading scheme
that ranged from 0 to 5.
Table 1 Design of the therapy study including the average tumor volumes and body weights of mice at therapy start






Day 0 Day 0
A Vehicle1 9 - 84 ± 24 23.7 ± 2.7
B [177Lu]Lu-6R-RedFol-1 6 10 MBq, 0.5 nmol 66 ± 8 24.6 ± 1.2
C [177Lu]Lu-OxFol-1 6 10 MBq, 0.5 nmol 69 ± 22 24.9 ± 1.2
D [177Lu]Lu-6R-RedFol-1 6 15 MBq, 0.5 nmol 99 ± 33 20.0 ± 0.83
E [177Lu]Lu-OxFol-1 6 15 MBq, 0.5 nmol 95 ± 20 20.9 ± 1.23
1Vehicle: 0.05% BSA in PBS
2No significant differences determined between the tumor volumes measured for each group (p > 0.05);
3 Significantly lower body weights compared with mice of groups A, B, and C
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Statistical analysis and figure preparation
Binding affinity to plasma proteins was statistically analyzed
using one-way ANOVAwith Dunnett’s multiple comparisons
post-test. Analyses of biodistribution data and the absolute
AUC0→ 120h values were performed with two-way or one-
way ANOVA with Tukey’s multiple comparisons post-test.
The therapy study was analyzed for significance using a one-
way ANOVA with Tukey’s or Dunnett’s test. Survival of
mice was assessed using Kaplan-Meier curves to determine
median survival of mice of each group. All analyses were
performed using GraphPad Prism program (version 7.0). A
p value of < 0.05 was considered statistically significant.
Graphs of Figs. 2 and 4 were prepared using GraphPad
Prism software (version 7).
Results
Radiolabeling, stability, and logD values of 177Lu-
folate conjugates
Radiolabeling with lutetium-177 was readily achieved to
obtain the folate radioconjugates at a radiochemical pu-
rity of > 99% (Supplementary Material, Fig. S1). All
folate radioconjugates were stable in PBS at room tem-
perature (> 97% intact radioconjugates) over 24 h
(Supplementary Material, Table S1). High stability was
also determined after incubat ion of the folate
radioconjugates in human plasma (≥ 98% intact
radioconjugates) over 24 h at 37 °C. The logD values
of [177Lu]Lu-6R-RedFol-1 (− 3.92 ± 0.11) and [177Lu]Lu-
6S-RedFol-1 (− 3.70 ± 0.10) were slightly higher than
the logD value of [177Lu]Lu-OxFol-1 (− 4.21 ± 0.14).
Binding affinity tomouse and human plasma proteins
At a physiological albumin concentration, represented
by the highest [mouse serum albumin (MSA)]-
to-[radioconjugate] molar ratio used in this study, ~
93% of [177Lu]Lu-6R-RedFol-1 and [177Lu]Lu-6S-
R e d F o l - 1 w e r e b o u n d t o p l a sm a p r o t e i n s
(Supplementary Material, Fig. S2a). Under the same ex-
perimental conditions, the plasma-bound fraction of
[177Lu]Lu-OxFol-1 was slightly lower (~ 90%). The
binding at the corresponding molar ratio of human se-
rum albumin (HSA) was higher for a l l th ree
radioconjugates, but in analogy to the results obtained
with MSA, [177Lu]Lu-6R-RedFol-1 and [177Lu]Lu-6S-
RedFol-1 showed slightly stronger binding (97–99%)
than [177Lu]Lu-OxFol-1 (~ 94%) (Supplementary
Material, Fig. S2b). The values of a 50% binding in
mouse plasma (B50; determined by a semi-log plots)
were in the same range for [177Lu]Lu-6R-RedFol-1
(614 ± 129) and [177Lu]Lu-6S-RedFol-1 (627 ± 172), but
slightly higher for [177Lu]Lu-OxFol-1 (747 ± 252)
(Supplementary Material, Fig. S2a), resulting in a rela-
tive affinity of 1.2 for both [177Lu]Lu-6R-RedFol-1 and
[177Lu]Lu-6S-RedFol-1, as compared with [177Lu]Lu-
OxFol-1 which was set as 1.0. The B50 values obtained
in human plasma were considerably lower resulting in
[HSA]-to-[radioconjugate] molar ratios of 149 ± 26 for
[177Lu]Lu-6R-RedFol-1, 184 ± 51 for [177Lu]Lu-6S-
RedFol-1, and 211 ± 39 for [177Lu]Lu-OxFol-1
(Supplementary Material, Fig. S2b). This meant relative
Fig. 2 Graphs representing the AUC0→ 120h of non-decay-corrected
biodistribution data up to 120 h p.i. of the folate radioconjugates. a
[177Lu]Lu-6R-RedFol-1. b [177Lu]Lu-6S-RedFol-1. c [177Lu]Lu-OxFol-
1 (adapted with permission from Siwowska et al. 2017, Mol Pharm
14:523 [18]. Copyright 2020 American Chemical Society). Each data
point represents the average of a group of mice ± SD (n = 4)
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affinities of 1.4 and 1.2 for [177Lu]Lu-6R-RedFol-1 and
[177Lu]Lu-6S-RedFol-1, respectively.
Cell uptake and internalization studies
In vitro studies with KB tumor cells that express the FR re-
vealed a trend of higher uptake of [177Lu]Lu-6R-RedFol-1
(28–30%) and [177Lu]Lu-6S-RedFol-1 (42–53%) than for
[177Lu]Lu-OxFol-1 (20–26%). The internalized fraction of
[177Lu]Lu-6R-RedFol-1 (14–15%) and [177Lu]Lu-6S-
RedFol-1 (14–19%) was also increased as compared with
the internalized fraction of [177Lu]Lu-OxFol-1 (10–11%).
Co-incubation of KB tumor cells with excess of folic acid to
block FRs reduced the uptake to < 0.1%, indicating FR-
specific uptake of all investigated folate radioconjugates
(Supplementary Material, Fig. S3).
In vivo stability of folate radioconjugates
In vivo stability studies performed in mice without tumors
revealed ≥ 99% of intact folate radioconjugates in blood plas-
ma at 4 h after injection of [177Lu]Lu-6R-RedFol-1,
[177Lu]Lu-6S-RedFol-1, and [177Lu]Lu-OxFol-1.
Biodistribution studies
Biodistribution studies of the folate radioconjugates were per-
formed in KB tumor-bearing mice over a period of 5 days
(Table 2; Supplementary Material, Fig. S4, Tables S2/S3).
Retention of activity in the blood at 1 h p.i. was higher
(p < 0.05) for [177Lu]Lu-6R-RedFol-1 (23 ± 3% IA/g) and
[177Lu]Lu-6S-RedFol-1 (19 ± 2% IA/g) than for [177Lu]Lu-
OxFol-1 (7.9 ± 1.4% IA/g). At 24 h p.i., blood activity levels
were, however, below 3% IA/g in all cases. The uptake of
[177Lu]Lu-6R-RedFol-1 and [177Lu]Lu-6S-RedFol-1 in KB
tumors was significantly increased from 24 h onwards when
compared with the uptake of [177Lu]Lu-OxFol-1 (p < 0.05).
The maximum accumulation of [177Lu]Lu-6R-RedFol-1 in
KB tumor xenografts (47 ± 4% IA/g) was reached at 24 h
p.i., while in the case of [177Lu]Lu-6S-RedFol-1, the highest
uptake (51 ± 7% IA/g) was observed at 48 h p.i. Both values
were much higher than the maximum tumor uptake of
[177Lu]Lu-OxFol-1 (18 ± 3% IA/g at 24 h p.i.).
[177Lu]Lu-6R-RedFol-1 and [177Lu]Lu-OxFol-1 showed a
similar washout after they reached maximum kidney uptake
(24 ± 4% IA/g and 28 ± 3% IA/g, respectively) at 24 h. The
renal uptake of [177Lu]Lu-6S-RedFol-1 was much higher (69
± 7% IA/g; 24 h p.i.). In other tissues such as the liver, lungs,
spleen, and heart, the uptake of [177Lu]Lu-6R-RedFol-1 and
Table 2 Biodistribution data
obtained in KB tumor-bearing
mice at 1, 4, 24, 48, 72, and 120 h
after injection of [177Lu]Lu-6R-
RedFol-1, [177Lu]Lu-6S-RedFol-
1, and [177Lu]Lu-OxFol-1. Data
are shown as percentage of the
injected activity per gram of tissue
[% IA/g], representing the
average ± SD
1 h p.i. 4 h p.i. 24 h p.i. 48 h p.i. 72 h p.i. 120 h p.i.
[177Lu]Lu-6R-RedFol-1
Blood 23 ± 3 17 ± 1 5.4 ± 0.9 3.0 ± 0.4 1.0 ± 0.3 0.20 ± 0.13
Kidneys 8.4 ± 0.8 12 ± 1 24 ± 4 18 ± 1 19 ± 5 11 ± 2
Liver 3.3 ± 0.3 3.0 ± 0.2 1.3 ± 0.2 1.1 ± 0.2 0.61 ± 0.14 0.32 ± 0.05
Muscle 1.6 ± 0.2 1.4 ± 0.1 0.82 ± 0.22 0.82 ± 0.06 0.28 ± 0.08 0.28 ± 0.15
Bone 2.1 ± 0.3 1.9 ± 0.2 0.91 ± 0.22 0.75 ± 0.17 0.37 ± 0.09 0.19 ± 0.01
KB tumor 11 ± 1 20 ± 2 47 ± 4 39 ± 5 41 ± 12 23 ± 7
[177Lu]Lu-6S-RedFol-1
Blood 19 ± 2 15 ± 2 3.8 ± 0.9 1.0 ± 0.5 0.27 ± 0.11 0.05 ± 0.01
Kidneys 18 ± 2 33 ± 2 69 ± 7 64 ± 6 60 ± 10 28 ± 2
Liver 2.6 ± 0.1 2.3 ± 0.2 0.81 ± 0.22 0.46 ± 0.16 0.28 ± 0.07 0.16 ± 0.03
Muscle 1.6 ± 0.2 1.3 ± 0.1 0.47 ± 0.15 0.21 ± 0.05 0.13 ± 0.06 0.10 ± 0.01
Bone 2.0 ± 0.2 1.7 ± 0.2 0.53 ± 0.08 0.28 ± 0.08 0.16 ± 0.05 0.11 ± 0.01
KB tumor 14 ± 3 26 ± 1 46 ± 3 51 ± 7 42 ± 10 29 ± 3
[177Lu]Lu-OxFol-11
Blood 7.9 ± 1.4 2.3 ± 0.5 0.49 ± 0.08 0.19 ± 0.00 0.10 ± 0.02 0.02 ± 0.01
Kidneys 23 ± 4 22 ± 3 28 ± 3 19 ± 1 17 ± 2 9.5 ± 0.4
Liver 5.0 ± 1.3 3.1 ± 0.4 3.1 ± 1.0 1.9 ± 0.4 1.8 ± 0.6 0.93 ± 0.12
Muscle 1.3 ± 0.1 1.1 ± 0.2 1.0 ± 0.2 0.58 ± 0.26 0.50 ± 0.21 0.19 ± 0.06
Bone 1.6 ± 0.1 1.3 ± 0.2 0.74 ± 0.31 0.50 ± 0.09 0.29 ± 0.09 0.20 ± 0.04
KB tumor 11 ± 1 14 ± 2 18 ± 3 10 ± 1 8.6 ± 0.6 6.0 ± 1.7
1Data reproduced with permission from Siwowska et al. 2017, Mol Pharm 14:523 [18]. Copyright 2020
American Chemical Society
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[177Lu]Lu-6S-RedFol-1 was elevated at early timepoints but
cleared within 24 h. As a consequence of the distribution
profile, the tumor-to-kidney and tumor-to-liver ratios of
[177Lu]Lu-6R-RedFol-1 were significantly increased in com-
parison with [177Lu]Lu-OxFol-1, whereas in the case of
[177Lu]Lu-6S-RedFol-1, only tumor-to-liver ratios were im-
proved (Supplementary Material, Fig. S5).
The uptake of activity in KB tumors and kidneys at 1 h p.i.
of all folate radioconjugates was reduced to ~ 5–7% IA/g and
~ 5–9% IA/g, respectively, when folic acid was pre-injected to
block FRs in these tissues (Supplementary Material,
Table S4).
Determination of AUC
The AUC0→ 120h of the tumor uptake after injection of
[177Lu]Lu-6R-RedFol-1 and [177Lu]Lu-6S-RedFol-1 revealed
similar values, which were at least 3-fold higher than the re-
spective value of [177Lu]Lu-OxFol-1 (Fig. 2; Table 3;
Supplementary Material, Table S5) [18]. The AUC0→ 120h
of kidney uptake was ~ 3-fold higher for [177Lu]Lu-6S-
RedFol-1 than for [177Lu]Lu-6R-RedFol-1 and [177Lu]Lu-
OxFol-1. Consequently, [177Lu]Lu-6R-RedFol-1 revealed a
3.6-fold increased tumor-to-kidney AUC0→ 120h ratio as com-
pared with [177Lu]Lu-OxFol-1, while tumor-to-kidney
AUC0 → 120h ratios of [
177Lu]Lu-6S-RedFol-1 and
[177Lu]Lu-OxFol-1 were similar (Table 3). The tumor-to-
blood AUC0→ 120h ratio of [
177Lu]Lu-6R-RedFol-1 was lower
than for [177Lu]Lu-OxFol-1 while no change in this regard
was observed for [177Lu]Lu-6S-RedFol-1. The tumor-to-liver
AUC0→ 120h ratios of [
177Lu]Lu-6R-RedFol-1 and [177Lu]Lu-
6S-RedFol-1 were 6-fold and 11-fold higher as compared with
the tumor-to-liver AUC0→ 120h ratio of [
177Lu]Lu-OxFol-1.
SPECT/CT imaging studies
The SPECT/CT images of mice injected with [177Lu]Lu-6R-
RedFol-1 showed high accumulation of activity in the tumors
and less in the kidneys as compared with [177Lu]Lu-OxFol-1
(Fig. 3). The same high tumor uptake was observed after
injection of [177Lu]Lu-6S-RedFol-1; however, in this case al-
so, the kidney uptake was increased. [177Lu]Lu-OxFol-1 dem-
onstrated lower activity in the tumor tissue and a similar kid-
ney retention as observed for [177Lu]Lu-6R-RedFol-1. The
images visualized clearly higher tumor-to-kidney ratios of
[177Lu]Lu-6R-RedFol-1 as compared with [177Lu]Lu-6S-
RedFol-1 and [177Lu]Lu-OxFol-1. Pre-injection of mice with
folic acid resulted in an almost entire blockade of the tumor
and kidney accumulation of all three radioconjugates up to 4 h
p.i. In order to block the uptake efficiently also at 24 h p.i.,
pre-injection of excess albumin-binding folate (cm13) was,
however, necessary in particular in the case of [177Lu]Lu-6S-
RedFol-1 (Supplementary Material, Figs. S6–S8).
Therapy study
The tumor size of untreated control mice (group A) was
constantly increasing over time, whereas a considerable
tumor growth delay was observed in treated mice of
groups B–E. This was reflected by significantly in-
creased tumor growth delay indices (TGDI) in treated
groups as compared with control mice where the
TGDIs were defined as 1.0 (Fig. 4; Supplementary
Material, Tables S6/S7).
A significantly more pronounced tumor growth delay
was observed in mice treated with 10 MBq [177Lu]Lu-
6R-RedFol-1 (group B) than in the mice treated with
10 MBq [177Lu]Lu-OxFol-1 (group C) resulting in in-
creased TGDI2 (group B: 4.2 ± 0.6 vs. group C: 2.4 ±
0.3; p < 0.05) (Fig. 4a, b; Supplementary Material,
Tables S6/S7). Mice that received 15 MBq [177Lu]Lu-
6R-RedFol-1 (group D) showed complete remission of
the tumors. Consequently, it was not possible to calcu-
late TGDIs. Interestingly, the mice that received
15 MBq [177Lu]Lu-OxFol-1 (group E) had a TGDI2 of
4.5 ± 0.3 which was similar to the results observed with
10 MBq [177Lu]Lu-6R-RedFol-1 (p > 0.05). These find-
ings were also reflected by the tumor growth inhibition
(TGI) determined at day 14 when the first mouse of
control group had to be euthanized (Table 4).
Table 3 Areas under the curve up
to 120 h p.i. (AUC0→ 120h)
calculated as [(% IA/g)·h] and
tumor-to-background AUC0→ 120h
ratios presented as a value relative




KB tumor 3.2 ± 0.3 3.6 ± 0.3 1.0 ± 0.1
Blood 4.5 ± 0.2 3.3 ± 0.2 1.0 ± 0.1
Kidneys 0.90 ± 0.07 2.8 ± 0.2 1.0 ± 0.1
Liver 0.53 ± 0.02 0.32 ± 0.02 1.0 ± 0.2
Relative AUC0→ 120h ratios
AUCTu-to-AUCBl 0.71 ± 0.09 1.1 ± 0.2 1.0 ± 0.2
AUCTu-to-AUCKi 3.6 ± 0.6 1.3 ± 0.2 1.0 ± 0.1
AUCTu-to-AUCLi 6.1 ± 0.8 11 ± 2 1.0 ± 0.2
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The median survival of treated mice was increased
compared with the median survival of control mice
(group A) (Table 4). The median survival of 49 days
for mice treated with 10 MBq [177Lu]Lu-6R-RedFol-1
(group B) was much longer than for mice that received
10 MBq [177Lu]Lu-OxFol-1 (group C: 34 days). All
mice injected with 15 MBq [177Lu]Lu-6R-RedFol-1
(group D) survived until the end of the study at day
56, whereas mice that received 15 MBq [177Lu]Lu-
OxFol-1 (group E) had a median survival of only
44 days.
Assessment of the therapy study
The average relative body weight (1.00–1.08) was com-
parable in all groups of mice at day 14, when the first
mouse of the control group reached an endpoint
(Supplementary Material, Table S8). Organ-to-body
weight as well as organ-to-brain mass ratios may serve
as indicators of the health status, since it is known that
the brain of the mice does not increase in size after the
age of 3 weeks (Supplementary Material, Tables S9/
S10) [25, 26]. The calculated organ-to-brain mass ratios
Fig. 3 SPECT/CT images shown
as maximum intensity projections
(MIPs) of KB tumor-bearingmice
after injection of the 177Lu-folate
radioconjugates (25 MBq;
0.5 nmol per mouse). a–c MIPs
obtained at 4 h p.i. d–f MIPs
obtained at 24 h p.i. Tu, KB
tumor; Ki, kidney; Bl, urinary
bladder
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were in the same range for untreated mice and mice
treated with 10 MBq of the folate radioconjugates
(groups B/C). The organ-to-brain mass ratios of mice
treated with 15 MBq of the folate radioconjugates
(groups D/E) were decreased (p < 0.05).
Blood plasma parameters determined at the time of
euthanasia did not differ among treated mice and un-
treated controls (Supplementary Material, Table S11).
Histological investigations of the kidneys, spleen, and
bone marrow did, however, not reveal any significant
lesion attributed to the treatment. In particular, bone
marrow of mice that received [177Lu]Lu-6R-RedFol-1
showed an overall hematopoietic cellularity comparable
to the control animals and mice treated with [177Lu]Lu-
OxFol-1 (Supplementary Material, Table S12).
Discussion
In this study, albumin-binding radioconjugates of a new class,
based on 5-MTHF as a FR-binding entity, were evaluated and
compared with the previously developed [177Lu]Lu-OxFol-1
[18]. [177Lu]Lu-6R-RedFol-1 and [177Lu]Lu-6S-RedFol-1
showed high stability in PBS and human plasma in vitro. In
all three cases, the binding to human plasma proteins was
stronger than to mouse plasma proteins, which is in line with
the reported affinity of the p-iodophenyl entity [27] and re-
cently reported results obtained with albumin-binding PSMA-
targeted radioligands [23]. In vitro studies revealed that the
exchange of folic acid with 5-MTHF slightly increased the
affinity of the respective radioconjugates to both mouse and
human plasma proteins when compared with the affinity
Table 4 Data regarding
euthanasia period and median
survival of mice





A 0.05% BSA/PBS 14–48 22 0
B [177Lu]Lu-6R-RedFol-1 (10 MBq) 44–56* 49 89 ± 3
C [177Lu]Lu-OxFol-1 (10 MBq) 26–38 34 66 ± 12
D [177Lu]Lu-6R-RedFol-1 (15 MBq) 56* n.d. 96 ± 2
E [177Lu]Lu-OxFol-1 (15 MBq) 42–54 44 91 ± 4
n.d. = not determined since all mice survived until the end of the study
*Day 56 = end of the study
Fig. 4 a Tumor growth curves
relative to the tumor volume at
day 0 (set as 1.0) for mice that
received PBS (group A), mice
treated with [177Lu]Lu-6R-
RedFol-1 (group B/D) or
[177Lu]Lu-OxFol-1 (group C/E).
b TGDI2, TGDI5, and TGDI8
determined for respective groups
(TGDIs of group D were not
determined due to RTV below the
threshold value). c Kaplan-Meier
plot of groups A–E. d Relative
body weight of groups A–E.
Tumor growth and body weights
are shown until the first mouse of
the respective group reached the
endpoint
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determined for [177Lu]Lu-OxFol-1. It remains, however, un-
clear whether this was the reason for the increased blood re-
tention of 5-MTHF-based folate radioconjugates or if it was
due to another, yet unknown, mechanism. The hypothesis that
the observed phenomenon was due to radiometabolite forma-
tion was refuted by stability experiments that showed only
intact folate radioconjugates in the blood plasma of mice 4 h
after injection. The FR-specific in vitro uptake of the
radioconjugates into KB tumor cells was demonstrated in
vivo, since / in vivo, as pre-injection of excess folic acid re-
duced the ac-cumulation of the radioconjugates in tumors and
kidneys of mice.The application of excess non-labeled albu-
min-binding folic acid conjugate (cm13) was, however, much
more effective in this regard due to its enhanced blood circu-
lation similar to the folate radioconjugates in question.
[177Lu]Lu-6R-RedFol-1 and [177Lu]Lu-6S-RedFol-1
showed a somewhat higher in vitro uptake and internalization
in FR-positive KB tumor cells as compared with [177Lu]Lu-
OxFol-1, and the in vivo results revealed even a 3–4-fold
increased tumor uptake of [177Lu]Lu-6R-RedFol-1 and
[177Lu]Lu-6S-RedFol-1. The in vivo results were likely due
to the enhanced blood retention of the 5-MTHF-based
radioconjugates; however, it may also be due to the easier
release of 5-MTHF from the FR upon internalization and,
thus, more efficient accumulation as compared with folic acid
[28]. The latter hypothesis is further supported by the results
of Boss et al. who observed an increased tumor uptake of 18F-
labeled 5-MTHF radiotracers as compared with the folic acid
analogue even though these radiotracers did not comprise an
albumin-binding entity [21]. In parallel to the increased tumor
uptake, [177Lu]Lu-6S-RedFol-1 showed also higher retention
in the kidneys resulting in similar tumor-to-kidney ratios as
observed with [177Lu]Lu-OxFol-1. In the case of [177Lu]Lu-
6R-RedFol-1, the retention in the kidneys remained relatively
low resulting in substantially improved tumor-to-kidneys
AUC0→ 120h ratios to a value that has never been achieved
before. This radioconjugate was, thus, selected for further in-
vestigations in a preclinical therapy study.
As expected, the treatment of KB tumor-bearing mice with
10 MBq or 15 MBq [177Lu]Lu-6R-RedFol-1, showed an
activity-dependent tumor growth inhibition and survival of
mice. In line with the higher tumor uptake, the outcome of
the [177Lu]Lu-6R-RedFol-1 therapy was superior over that of
[177Lu]Lu-OxFol-1. Comparison of the TGDI and TGI results
suggested that the application of 10 MBq [177Lu]Lu-6R-
RedFol-1 was equipotent to the application of 15 MBq
[177Lu]Lu-OxFol-1 which confirmed the enhanced therapeu-
tic potential of this novel radioconjugate.
As the tumor-to-kidney AUC0→ 120h ratio of [
177Lu]Lu-6R-
RedFol-1was almost 4-fold increased comparedwith [177Lu]Lu-
OxFol-1, the use of [177Lu]Lu-6R-RedFol-1 would most proba-
bly allow delivering an effective tumor dose without the risk of
long-term damage to the kidneys. In our study, no obvious early
side effects were observed. Neither the body weights nor the
blood plasma parameters of treated mice were significantly dif-
ferent from the control values. Moreover, no significant histo-
pathological changes in kidneys and spleen were observed that
would indicate radiation-induced damage of these tissues. Most
importantly, the evaluation of the bone marrow of mice treated
with [177Lu]Lu-6R-RedFol-1 confirmed the absence of hemato-
logical side effects, in spite of the enhanced blood retention of
this novel radioconjugate.
Conclusion
It was demonstrated in this study that 5-MTHF-based
radioconjugates have the potential to be used for targeted ra-
dionuclide therapy. Due to the unprecedentedly high tumor-
to-kidney rat ios of [177Lu]Lu-6R-RedFol-1, this
radioconjugate outperformed any other folate radioconjugate.
It was, thus, shown to have enhanced therapeutic efficacy as
compared with [177Lu]Lu-OxFol-1, which makes [177Lu]Lu-
6R-RedFol-1 attractive for clinical translation.
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